ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1784

Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid PsA: Analysis of CorEvitas’ Psoriasis Registry

Alexis Ogdie-Beatty1, Bruce Strober2, Mark Lebwohl3, Angel Cronin4, Tin-chi Lin4, Hyung-Joo Kang4, Nicole Middaugh4, Jacqueline O’Brien4, Shauna Jardon5, Sven Richter6, Yuri Klyachkin7 and Philip Mease8, 1University of Pennsylvania, Philadelphia, PA, 2Yale University, New Haven, CT, 3Icahn School of Medicine at Mount Sinai, New York, NY, 4CorEvitas, LLC, Waltham, MA, 5Amgen Inc., Gilbert, AZ, 6Amgen Inc., Thousand Oaks, CA, 7Amgen Inc., Lexington, KY, 8Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA

Meeting: ACR Convergence 2021

Keywords: psoriasis, skin

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Session Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Patients (pts) with mild to moderate psoriasis (PsO) and musculoskeletal disease burden may be diagnosed with PsA upon referral to a rheumatologist. Early intervention in pts with PsA may result in improved joint, skin, and quality-of-life (QoL) outcomes. This analysis of CorEvitas’ Psoriasis Registry sought to identify characteristics and musculoskeletal disease burden among pts naive to systemic treatment with mild to moderate psoriasis based on evidence of potential comorbid PsA.

Methods: The prospective, observational CorEvitas’ Psoriasis Registry enrolls adults with dermatologist-diagnosed PsO who initiated or switched to an eligible systemic treatment at enrollment or within 12 months before enrollment. Pts with mild to moderate PsO (Investigator Global Assessment: 2 or 3) initiating first systemic treatment at enrollment (April 2015‒June 2020) were grouped by musculoskeletal disease burden. This descriptive analysis compares pts with no evidence of PsA (no dermatologist-reported PsA and negative Psoriasis Epidemiology Screening Tool [PEST] screen [< 3]) to pts with dermatologist-reported PsA and to pts without dermatologist-reported PsA but positive PEST (≥3). Standardized differences were calculated (potentially meaningful difference: d > 0.1; moderate difference: d > 0.5).

Results: Of the 1,113 pts enrolled, 766 (68.8%) had no evidence of PsA, 237 (21.3%) had dermatologist-reported PsA, and 110 (9.9%) had a positive PEST screen (PEST ≥3) without dermatologist-reported PsA. Concordance between dermatologist-reported PsA and positive PEST screen was 80%: 112 pts (10%) had dermatologist-reported PsA and negative PEST screen and 110 pts (10%) had positive PEST screen without dermatologist-reported PsA. For all groups, mean PsO duration was >9 years. For pts with dermatologist-reported PsA, mean PsA duration was 4 years (Table). Comorbidity histories were often higher in pts with dermatologist-reported PsA or positive PEST screen without dermatologist-reported PsA vs pts with no evidence of PsA (Table). Current employment was less prevalent among pts with dermatologist-reported PsA or positive PEST screen without dermatologist-reported PsA vs pts with no evidence of PsA (Table). Mean skin pain visual analog scale (VAS) and fatigue VAS scores were higher for pts with dermatologist-reported PsA or positive PEST screen without dermatologist-reported PsA vs no evidence of PsA (Figure 1). Also, EuroQol-5 Dimension 3 Level assessments indicated that pts with dermatologist-reported PsA or positive PEST screen without dermatologist-reported PsA had greater problems with mobility, pain and comfort, and anxiety and depression compared with pts with no evidence of PsA (Figure 2).

Conclusion: Pts naive to systemic treatment who have mild to moderate PsO and either PsA or musculoskeletal disease suggestive of comorbid PsA had greater comorbidity burden, symptom burden, and QoL impairment compared with pts with no evidence of PsA in this analysis from CorEvitas’ Psoriasis Registry.

Table

Figure 1

Figure 2


Disclosures: A. Ogdie-Beatty, AbbVie, 2, Amgen, 2, 5, BMS, 2, Celgene, 2, CorEvitas (formerly Corrona), 2, Janssen, 2, Eli Lilly, 2, Novartis, 2, Pfizer, 2, UCB, 2, National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, 5, Rheumatology Research Foundation, 5, National Psoriasis Foundation, 5, Pfizer (to University of Pennsylvania), 5, AbbVie (to University of Pennsylvania), 5, Novartis (to University of Pennsylvania), 5, Gilead, 2; B. Strober, AbbVie, Amgen, Eli Lilly, Janssen, Sanofi-Genzyme, 6, AbbVie, Cara, CorEvitas’ Psoriasis Registry, Dermavant, Dermira, and Novartis, 12, Investigator, Journal of Psoriasis and Psoriatic Arthritis, 6, 12, Editor-in-Chief (honorarium), CorEvitas’ Psoriasis Registry, 2, 12, co-scientific director (consulting fee), AbbVie, Almirall, Amgen Inc., Arcutis, Arena, Aristea, Boehringer Ingelheim, Bristol Myers Squibb, 2, 6, Connect Biopharma, Dermavant, Dermira, Eli Lilly, Equillium, GlaxoSmithKline, Immunic Therapeutics, 2, 6, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Mindera, Novartis, Ortho Dermatologics, 2, 6, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, and UCB, 2, 6; M. Lebwohl, Aditum Bio, 2, Abbvie, 5, Allergan, 2, Almirall, 2, Amgen, 5, Arcutis, Inc., 2, 5, Avotres Therapeutics, 2, BirchBioMed Inc., 2, BMD skincare, 2, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb, 2, Cara Therapeutics, 2, Castle Biosciences, 2, CorEvitas, LLC, 2, Dermavant Sciences, 2, 5, Evelo, 2, Eli Lilly, 5, Evommune, 2, 5, Facilitate International Dermatologic Education, 2, Foundation for Research and Education in Dermatology, 2, Inozyme Pharma, 2, Kyowa Kirin, 2, Leo Pharmaceutucals, 2, 5, Meiji Seika Pharma, 2, Incyte, 5, Janssen, 5, Menlo, 2, Mitsubishi, 2, Neuroderm, 2, Ortho Dermatologics, 5, Pfizer, 2, 5, Promius/Dr. Reddy’s Laboratories, 2, Serono, 2, Theravance, 2, Verrica, 2, UCB, 5; A. Cronin, CorEvitas, LLC, 3; T. Lin, CorEvitas, LLC, 3; H. Kang, CorEvitas, LLC, 3; N. Middaugh, CorEvitas, LLC, 3; J. O’Brien, CorEvitas, LLC, 3; S. Jardon, Amgen Inc., 3, 11; S. Richter, Amgen Inc., 3, 11; Y. Klyachkin, Amgen Inc., 3, 11; P. Mease, AbbVie, 2, 5, 6, Amgen, 2, 5, 6, Bristol-Myers Squibb, 2, 5, Eli Lilly, 2, 5, 6, Galapagos, 2, 5, Celgene, 2, Boehringer Ingelheim, 2, Genentech, 2, 5, 6, Janssen, 2, 5, 6, Gilead Sciences, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Sun Pharma, 2, 5, UCB Pharma, 2, 6, GSK, 2.

To cite this abstract in AMA style:

Ogdie-Beatty A, Strober B, Lebwohl M, Cronin A, Lin T, Kang H, Middaugh N, O’Brien J, Jardon S, Richter S, Klyachkin Y, Mease P. Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid PsA: Analysis of CorEvitas’ Psoriasis Registry [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/characterizing-musculoskeletal-disease-burden-in-mild-to-moderate-psoriasis-patients-suggestive-of-comorbid-psa-analysis-of-corevitas-psoriasis-registry/. Accessed January 28, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterizing-musculoskeletal-disease-burden-in-mild-to-moderate-psoriasis-patients-suggestive-of-comorbid-psa-analysis-of-corevitas-psoriasis-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences